Biomarkers for the Diagnosis of Alzheimer’s Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: International Journal of Molecular Sciences 23.15 (2022): 8598.
- Ereignis
-
Veröffentlichung
- (wo)
-
Erlangen
- (wer)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (wann)
-
2022
- Urheber
-
Dulewicz, Maciej
Kulczyńska-Przybik, Agnieszka
Mroczko, Piotr
Kornhuber, Johannes
Lewczuk, Piotr
Mroczko, Barbara
- DOI
-
10.3390/ijms23158598
- URN
-
urn:nbn:de:bvb:29-opus4-203649
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:45 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dulewicz, Maciej
- Kulczyńska-Przybik, Agnieszka
- Mroczko, Piotr
- Kornhuber, Johannes
- Lewczuk, Piotr
- Mroczko, Barbara
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Entstanden
- 2022
Ähnliche Objekte (12)
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4
Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer’s disease
Structural imaging biomarkers of Alzheimer's disease : predicting disease progression
Selecting biomarkers for pluripotency and Alzheimer's disease : the real strength of the GA, SVM
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Regional cerebral associations between psychometric tests and imaging biomarkers in Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Peripheral blood as a potential source for Alzheimer's disease biomarkers
Biomarkers in Alzheimer's disease and lewy body disorders with dementia.
Improved risk prediction of all-cause dementia, Alzheimer’s disease, and vascular dementia by biomarkers of oxidative stress and inflammation
Detection of novel serological biomarkers in two neurodegenerative disorders : Morbus Alzheimer and multiple sclerosis
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4
Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer’s disease
Structural imaging biomarkers of Alzheimer's disease : predicting disease progression
Selecting biomarkers for pluripotency and Alzheimer's disease : the real strength of the GA, SVM
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Regional cerebral associations between psychometric tests and imaging biomarkers in Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Peripheral blood as a potential source for Alzheimer's disease biomarkers
Biomarkers in Alzheimer's disease and lewy body disorders with dementia.
Improved risk prediction of all-cause dementia, Alzheimer’s disease, and vascular dementia by biomarkers of oxidative stress and inflammation
Detection of novel serological biomarkers in two neurodegenerative disorders : Morbus Alzheimer and multiple sclerosis
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4
Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer’s disease
Structural imaging biomarkers of Alzheimer's disease : predicting disease progression
Selecting biomarkers for pluripotency and Alzheimer's disease : the real strength of the GA, SVM
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Regional cerebral associations between psychometric tests and imaging biomarkers in Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Peripheral blood as a potential source for Alzheimer's disease biomarkers
Biomarkers in Alzheimer's disease and lewy body disorders with dementia.
Improved risk prediction of all-cause dementia, Alzheimer’s disease, and vascular dementia by biomarkers of oxidative stress and inflammation